阳光诺和：拟1500万元认缴元码智药新增注册资本

Core Viewpoint - Sunshine Nuohuo (688621) announced an investment of 15 million yuan to acquire an 8.20% stake in Yuanma Zhiyao, which focuses on innovative research and development of circular mRNA CAR-T nucleic acid drugs, aiming to address unmet clinical needs in autoimmune diseases and tumors [1] Group 1 - The company is investing 15 million yuan to increase the registered capital of Yuanma Zhiyao by 110,600 yuan [1] - After the investment, the company will hold an 8.20% equity stake in Yuanma Zhiyao [1] - Yuanma Zhiyao specializes in the innovation and research of circular mRNA CAR-T nucleic acid drugs, aiming to revolutionize the commercialization challenges of CAR-T therapy [1] Group 2 - The investment aligns with the company's overall strategic layout in the field of in vivo CAR-T cell therapy and nucleic acid drugs [1] - The approach of using "nucleic acid drug form" to achieve "cell therapy effects" is intended to provide new solutions for patients with unmet clinical needs [1]